ABSTRACT
Matrix metalloproteinase-3 (MMP-3) can mediate the occurrence and development of rheumatoid arthritis (RA). The MMP3 promoter gene exhibits polymorphism with 5A/6A alleles. We investigated the correlation between the expression of MMP3 gene polymorphism and RA to provide an objective basis for prognosis evaluation. We enrolled 80 RA patients and 80 healthy subjects. Enzyme-linked immunosorbent assay was used to detect MMP-3 serum levels, pyrosequencing was used to test MMP3 genotypes, and real-time polymerase chain reaction determined MMP-3 mRNA expression levels. Compared with the control group, the serum level of MMP-3 in the RA patients increased significantly (P < 0.05). The serum level of MMP-3 in RA patients in the active period was markedly elevated compared with that in patients in the relief period (P < 0.05). There was no statistically significant difference between MMP3 gene frequency distribution in the RA patients and the control group (P > 0.05). MMP-3 mRNA expression in the RA patients was markedly upregulated compared with the control group (P < 0.05), while RA patients in the active period exhibited higher MMP-3 mRNA expression (P < 0.05). There was no significant difference in MMP-3 mRNA expression between RA patients with or without the 6A/6A genotype (P > 0.05). RA patients exhibited higher serum MMP-3 levels and mRNA expression, which were more obvious in the active period. MMP-3 is associated with the occurrence and development of RA bone erosion, and its serum level and mRNA expression can be treated as important predictors of joint damage.
Subject(s)
Arthritis, Rheumatoid/genetics , Gene Expression , Matrix Metalloproteinase 3/genetics , Polymorphism, Single Nucleotide , RNA, Messenger/genetics , Adolescent , Adult , Aged , Alleles , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/diagnosis , Case-Control Studies , Female , Gene Frequency , Genotype , Humans , Male , Matrix Metalloproteinase 3/blood , Middle Aged , Promoter Regions, Genetic , Young AdultABSTRACT
This study aimed to investigate the expressional profile of interleukin-6 (IL-6) in articular cartilage bone of osteoarthritis (OA) patients and its correlation with OA. A total of 30 articular cartilage bone samples from knee OA patients, which were collected by knee arthroscopy or articular surgery, comprised the study group, and 30 samples of normal articular cartilage tissue comprised the control group. Both mRNA (messenger ribonucleic acid) and protein levels of IL-6 and matrix metalloproteinase-9 (MMP-9) were measured and compared, and a correlation analysis was performed between the two. The integral optical density (IOD) values of MMP-9 and IL-6 proteins in the study group were 9.21 ± 3.22 and 8.94 ± 3.17, respectively; these were significantly higher (P < 0.05) than those in the control group at 3.14 ± 1.48 and 6.64 ± 1.53, respectively. The IOD values of mRNA transcripts for MMP-9 and IL-6 in the study group were 8.31 ± 2.28 and 8.78 ± 3.43, respectively; these were significantly higher than the values in the control group at 3.52 ± 1.37 and 5.21 ± 1.72 (P < 0.05), respectively. Further, the correlation analysis revealed significantly positive relationships for both protein (r = 0.434, P = 0.001) and mRNA (r = 0.413, P = 0.002) levels between MMP-9 and IL-6. In conclusion, articular cartilage tissues in knee OA patients have higher levels of MMP-9 and IL-6 expression, and these may play a synergistic role in OA pathogenesis.
Subject(s)
Cartilage, Articular/metabolism , Cartilage, Articular/pathology , Interleukin-6/biosynthesis , Osteoarthritis, Knee/metabolism , Osteoarthritis, Knee/pathology , Adult , Aged , Case-Control Studies , Female , Genetic Association Studies , Humans , Interleukin-6/genetics , Male , Matrix Metalloproteinase 3/genetics , Matrix Metalloproteinase 3/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Middle Aged , Osteoarthritis, Knee/genetics , RNA, Messenger/genetics , TranscriptomeABSTRACT
We investigated the expression levels of high-mobility group box protein 1 (HMGB-1), CXC chemokine ligand 16 (CXCL16), microRNA (miRNA)-30a and transforming growth factor ß1 (TGF-ß1) in primary nephritic syndrome (PNS) patients and the clinical significance of this expression. A total of 56 patients with PNS were included in the PNS group, while 50 healthy subjects formed the normal control group. Serum levels of HMGB-1, CXCL16, miRNA-30a, and urinary TGF-ß1 concentrations were quantified along with other biochemical indices, including serum albumin, triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein, and urinary proteins. The correlation between levels of HMGB-1, CXCL16, miRNA-30a, and TGF-ß1 and biochemical indexes was further analyzed. PNS group patients had significantly higher levels of HMGB-1, CXCL16, miRNA- 30a, and TGF-ß1 compared to the control group (P < 0.05). PNS patients also had higher 24-h urinary protein, TG, TC, and LDL levels but lower serum albumin compared to subjects in the control group (P < 0.05). Serum HMGB-1, CXCL16, miRNA-30a, and urinary TGF-ß1 levels were all negatively correlated with serum albumin levels, but were positively correlated with TG, TC, LDL, and 24-h urinary protein (P < 0.05 in all cases). Additionally, a positive correlation existed among serum HMGB-1, CXCL16, miRNA-30a, and urinary TGF-ß1 levels (P < 0.01). HMGB-1, CXCL16, miRNA-30a, and urinary TGF-ß1 were highly expressed in PNS patients and may play important roles in the pathogenesis and development of PNS.
